))
6: From Approval to Access
Manage episode 493975234 series 3675738
Content provided by The HEII. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The HEII or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Gilead’s twice-yearly injectable PrEP, Yeztugo was recently approved by the FDA, but the story doesn’t end there. In this episode of The Biotech Brief, we explore how Gilead is leveraging global partnerships, generics, and regulatory streamlining to deliver Yeztugo to low- and middle-income countries without delay. Building on Episode 1, “Changing the Game in HIV Prevention,” this follow-up digs into what equitable access really takes and what drug developers can learn from it.
6 episodes
Share
